SG10201901426WA - Ophthalmic composition - Google Patents

Ophthalmic composition

Info

Publication number
SG10201901426WA
SG10201901426WA SG10201901426WA SG10201901426WA SG10201901426WA SG 10201901426W A SG10201901426W A SG 10201901426WA SG 10201901426W A SG10201901426W A SG 10201901426WA SG 10201901426W A SG10201901426W A SG 10201901426WA SG 10201901426W A SG10201901426W A SG 10201901426WA
Authority
SG
Singapore
Prior art keywords
ophthalmic composition
salt
hyaluronic acid
ophthalmic
composition
Prior art date
Application number
SG10201901426WA
Inventor
Takanori Ohno
Masahiro Kawahata
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of SG10201901426WA publication Critical patent/SG10201901426WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Abstract

OPHTHALMIC COMPOSITION The present invention addresses the problem of maintaining a high retention rate of the kinematic viscosity of an ophthalmic composition, such as an ophthalmic solution comprising hyaluronic acid or a salt thereof. Provided is an ophthalmic composition comprising 0.001-0.5% (w/v) of hyaluronic acid or a salt thereof, 0.0005-0.02% (w/v) of chlorhexidines, 0.03-1.5% (w/v) of propylene glycol, and 0.015% (w/v) or less of ethylenediaminetetraacetates. (No Suitable Figure)
SG10201901426WA 2015-03-06 2016-03-04 Ophthalmic composition SG10201901426WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015045065 2015-03-06

Publications (1)

Publication Number Publication Date
SG10201901426WA true SG10201901426WA (en) 2019-03-28

Family

ID=56880167

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201707117SA SG11201707117SA (en) 2015-03-06 2016-03-04 Ophthalmic composition
SG10201901426WA SG10201901426WA (en) 2015-03-06 2016-03-04 Ophthalmic composition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201707117SA SG11201707117SA (en) 2015-03-06 2016-03-04 Ophthalmic composition

Country Status (7)

Country Link
JP (2) JP6716293B2 (en)
KR (1) KR102607126B1 (en)
MY (1) MY190393A (en)
PH (1) PH12017501567A1 (en)
SG (2) SG11201707117SA (en)
TW (2) TW202114648A (en)
WO (1) WO2016143708A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190240251A1 (en) * 2016-10-14 2019-08-08 i.com medical GmbH Method for establishing, restoring, and preserving homeostasis of the ocular surface
JP6603785B2 (en) * 2017-12-08 2019-11-06 千寿製薬株式会社 Aqueous solution containing water-soluble polymer
CN114845734A (en) * 2019-12-27 2022-08-02 乐敦制药株式会社 Aqueous composition
CN112870216A (en) * 2021-01-29 2021-06-01 张宽才 Pharmaceutical composition, preparation and application
JP2023022569A (en) * 2021-08-03 2023-02-15 小林製薬株式会社 Eyewash composition
CN114391550B (en) * 2022-01-06 2022-11-22 江南大学 Water-soluble chlorhexidine antibacterial agent and preparation method and application thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1072376A (en) * 1996-09-02 1998-03-17 Ofutekusu:Kk Eye drop aqueous solution comprising hyaluronic acid
JPH1160505A (en) * 1997-05-20 1999-03-02 Senju Pharmaceut Co Ltd Antiseptic composition
JPH115744A (en) * 1997-06-16 1999-01-12 Toa Yakuhin Kk Aqueous solution preparation for external use containing hyaluronic acid
JP2002193815A (en) * 2000-12-25 2002-07-10 Ophtecs Corp Eye drops for prevention of corneal drying for ophthalmic operation
JP2003002837A (en) * 2001-06-21 2003-01-08 Lion Corp Composition for aqueous skin care preparation and method for preventing clouding of liquid composition
JP4431817B2 (en) 2002-03-08 2010-03-17 第一三共株式会社 Eye drops containing tetrazole derivatives
JP4694773B2 (en) * 2003-06-06 2011-06-08 ロート製薬株式会社 Mucosal liquid composition
WO2006020994A2 (en) * 2004-08-13 2006-02-23 Angiotech International Ag Compositions and methods using hyaluronic acid and hyluronidase inhibitors
CN101528239B (en) 2006-10-26 2013-03-13 千寿制药株式会社 Ophthalmic aqeous liquid preparation
JP5595206B2 (en) * 2009-09-30 2014-09-24 ロート製薬株式会社 Ophthalmic liquid composition
CN103608000B (en) * 2011-06-23 2016-05-11 参天制药株式会社 The eye drops that contains hyaluronic acid or its salt and propane diols

Also Published As

Publication number Publication date
WO2016143708A1 (en) 2016-09-15
JP2016166195A (en) 2016-09-15
KR102607126B1 (en) 2023-11-27
JP2020138979A (en) 2020-09-03
SG11201707117SA (en) 2017-10-30
TW202114648A (en) 2021-04-16
MY190393A (en) 2022-04-20
KR20170122773A (en) 2017-11-06
TW201705948A (en) 2017-02-16
TWI745287B (en) 2021-11-11
JP6716293B2 (en) 2020-07-01
PH12017501567A1 (en) 2018-02-05

Similar Documents

Publication Publication Date Title
MY190393A (en) Ophthalmic composition
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
MY189454A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
SG11201804121RA (en) Novel biphenyl compound or salt thereof
MX2022001291A (en) Stereochemically enriched compositions for delivery of nucleic acids.
MX2020006612A (en) Compound functioning as bromodomain protein inhibitor, and composition.
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
TN2016000529A1 (en) Substituted dihydroisoquinolinone compounds
MX2016015565A (en) Certain protein kinase inhibitors.
MX2018010788A (en) Ophthalmological composition.
WO2016044463A3 (en) Mk2 inhibitors and uses thereof
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
MX2020001793A (en) Ahr inhibitors and uses thereof.
MX2018003554A (en) Isoxazoline-substituted benzamides and analogues as insecticides.
JOP20200323A1 (en) Methods of manufacturing amino acid compositions
CR20200275A (en) Hydroxyisoxazolines and derivatives thereof
WO2019078968A3 (en) Cyclic compounds as immunomodulating agents
WO2018039077A8 (en) Therapeutic compounds
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
PH12019500198A1 (en) Compounds and compositions and uses thereof
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
MX2017010277A (en) Cenicriviroc for the treatment of fibrosis.